PFE

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Pfizer Inc.

Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives. It strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with its responsibility as one of the world's premier innovative biopharmaceutical companies, it collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, it has worked to make a difference for all who rely on it. It routinely posts information that may be important to investors on its website at www.Pfizer.com.
CEO
Albert Bourla
Employees
78500
Headquarters

235 E 42nd St
New York, New York 10017-5703
Phone: 12125732323
www.pfizer.com

News

Wall Street''s Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields
Jul 15, 2024 18:08pm

During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout . Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga''s extensive database of analyst ratings, including by analyst accuracy . Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Pfizer Inc. (NYSE: PFE ) Dividend Yield: 5.81% Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating with a price target of $45 on July 10. This analyst has an accuracy rate of 70%. BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and raised the price target from $33 to $36 on May 2. This analyst has an accuracy rate of 70%. Recent News: On July 11, Pfizer announced it selected its preferred once-daily …


Source:Benzinga
Pfizer Stock (NYSE:PFE): Super Cheap, 5.7% Yield, Potential Weight Loss Catalyst
Jul 15, 2024 16:10pm

Pfizer ($PFE) stock has been struggling, but looking among the market’s laggards can yield attractive opportunities. The stock is super cheap, spor…


Source:TipRanks
Pfizer''s weight loss pill, Novo Nordisk''s setback, and the FTC vs. drug middlemen: Pharma news roundup
Jul 12, 2024 15:46pm

… that pharmacy benefit managers (PBMs) are hiking the price of drugs . Check … out those stories and more pharmaceutical news highlights …


Source:EIN News Pharmaceuticals
Pfizer, L3Harris Technologies And More: CNBC''s ''Final Trades''
Jul 12, 2024 13:14pm

Joshua Brown of Ritholtz Wealth Management named Pfizer Inc. (NYSE: PFE ) as his final trade on the latest edition of CNBC''s “ Halftime Report Final Trades .” On Thursday, Pfizer announced it will advance the development of Danuglipron. The company selected the once-daily weight loss drug for continued advancement based on an ongoing pharmacokinetic study . "Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several pre-clinical candidates," said Mikael Dolsten, chief scientific officer & president, … Full story available on Benzinga.com


Source:Benzinga
Pfizer advances development of once-daily danuglipron
Jul 12, 2024 07:30am

The company plans to conduct dose optimization studies with a focus on the preferred formulation to inform the registration enabling studies The post Pfizer advances development of once-daily danuglipron appeared first on Express Pharma .


Source:Express Pharma
Pfizer moves forward with once-daily weight-loss pill to compete with Wegovy
Jul 11, 2024 23:33pm

Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday.


Source:New York Post
Pfizer is far behind weight loss drug race despite pill trial, says Mizuho''s Jared Holz
Jul 11, 2024 22:32pm

Jared Holz, Mizuho, joins ''Fast Money'' to talk what impact, if any, the Pfizer weight-loss drug trial will have on the stock.


Source:CNBC
Pfizer moving forward with once-daily weight-loss pill seen as potential injection alternative
Jul 11, 2024 22:30pm

Pfizer wants a piece of the Ozempic/Wegovy pie. It''s developing a once-daily weight-loss drug that could be an alternative to the diabetes treatment injections also used in the obesity market.


Source:WMAR-2 News
Pfizer to move daily weight-loss pill to clinical trials
Jul 11, 2024 20:11pm

Firm says drug Danuglipron has shown ‘encouraging’ signs in early studies


Source:Evening Standard
Three-Stock Lunch: Apple, Pfizer and Delta Air Lines
Jul 11, 2024 18:56pm

Michael Farr, Hightower Advisors chief investment strategist, joins ''Power Lunch'' to discuss stock plays for three stocks.


Source:CNBC